Cargando…
Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design
The disease produced by the new coronavirus known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), named COVID-19 (Coronavirus Disease-2019) has recently been classified as a pandemic by the World Health Organization (WHO). However, scarce clinical data is available and generally lim...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510540/ https://www.ncbi.nlm.nih.gov/pubmed/32989425 http://dx.doi.org/10.1016/j.conctc.2020.100654 |
_version_ | 1783585809245405184 |
---|---|
author | Núñez-Gil, Iván J. Estrada, Vicente Fernández-Pérez, Cristina Feltes, Gisela Vedia, Oscar Vergara-Uzcategui, Carlos E. Moreno-Menguía, Víctor H. Cerrato, Enrico D'Ascenzo, Fabrizio Raposeiras-Roubin, Sergio Martín-Sánchez, F. Javier Alfonso-Rodríguez, Emilio Huang, Jia Ramakrishna, Harish Gil-Higes, Emma Fernández-Ortiz, Antonio Macaya, Carlos |
author_facet | Núñez-Gil, Iván J. Estrada, Vicente Fernández-Pérez, Cristina Feltes, Gisela Vedia, Oscar Vergara-Uzcategui, Carlos E. Moreno-Menguía, Víctor H. Cerrato, Enrico D'Ascenzo, Fabrizio Raposeiras-Roubin, Sergio Martín-Sánchez, F. Javier Alfonso-Rodríguez, Emilio Huang, Jia Ramakrishna, Harish Gil-Higes, Emma Fernández-Ortiz, Antonio Macaya, Carlos |
author_sort | Núñez-Gil, Iván J. |
collection | PubMed |
description | The disease produced by the new coronavirus known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), named COVID-19 (Coronavirus Disease-2019) has recently been classified as a pandemic by the World Health Organization (WHO). However, scarce clinical data is available and generally limited to the Chinese population due to the first cases were identified in Wuhan (Hubei, China). This article describes the rationale and design of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) registry (ClinicalTrials.gov Identifier: NCT04334291). With an ambispective cohort design, eligible patients are those discharged, deceased or alive, from any hospital center with a confirmed diagnosis or a COVID-19 high suspicion. With a current recruitment of more than 7000 cases, in 46 hospitals in 8 countries, since it is not possible to estimate the sample size based on literature reports, the investigators will try to get the maximum numbers of patients possible. The study primary objective is all cause mortality and aims to characterize the clinical profile of patients infected in order to develop a prognostic clinical score allowing, rapid logistic decision making. As secondary objectives, the analysis of other clinical events, the risk-adjusted influence of treatments and previous comorbidities of patients infected with the disease will be performed. The results of HOPE COVID-19 will contribute to a better understanding of this condition. We aim to describe the management of this condition as well as the outcomes in relation to the therapy chosen, in order to gain insight into improving patient care in the coming months. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov. Unique identifier: NCT04334291. |
format | Online Article Text |
id | pubmed-7510540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-75105402020-09-24 Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design Núñez-Gil, Iván J. Estrada, Vicente Fernández-Pérez, Cristina Feltes, Gisela Vedia, Oscar Vergara-Uzcategui, Carlos E. Moreno-Menguía, Víctor H. Cerrato, Enrico D'Ascenzo, Fabrizio Raposeiras-Roubin, Sergio Martín-Sánchez, F. Javier Alfonso-Rodríguez, Emilio Huang, Jia Ramakrishna, Harish Gil-Higes, Emma Fernández-Ortiz, Antonio Macaya, Carlos Contemp Clin Trials Commun Article The disease produced by the new coronavirus known as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), named COVID-19 (Coronavirus Disease-2019) has recently been classified as a pandemic by the World Health Organization (WHO). However, scarce clinical data is available and generally limited to the Chinese population due to the first cases were identified in Wuhan (Hubei, China). This article describes the rationale and design of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) registry (ClinicalTrials.gov Identifier: NCT04334291). With an ambispective cohort design, eligible patients are those discharged, deceased or alive, from any hospital center with a confirmed diagnosis or a COVID-19 high suspicion. With a current recruitment of more than 7000 cases, in 46 hospitals in 8 countries, since it is not possible to estimate the sample size based on literature reports, the investigators will try to get the maximum numbers of patients possible. The study primary objective is all cause mortality and aims to characterize the clinical profile of patients infected in order to develop a prognostic clinical score allowing, rapid logistic decision making. As secondary objectives, the analysis of other clinical events, the risk-adjusted influence of treatments and previous comorbidities of patients infected with the disease will be performed. The results of HOPE COVID-19 will contribute to a better understanding of this condition. We aim to describe the management of this condition as well as the outcomes in relation to the therapy chosen, in order to gain insight into improving patient care in the coming months. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov. Unique identifier: NCT04334291. Elsevier 2020-09-23 /pmc/articles/PMC7510540/ /pubmed/32989425 http://dx.doi.org/10.1016/j.conctc.2020.100654 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Núñez-Gil, Iván J. Estrada, Vicente Fernández-Pérez, Cristina Feltes, Gisela Vedia, Oscar Vergara-Uzcategui, Carlos E. Moreno-Menguía, Víctor H. Cerrato, Enrico D'Ascenzo, Fabrizio Raposeiras-Roubin, Sergio Martín-Sánchez, F. Javier Alfonso-Rodríguez, Emilio Huang, Jia Ramakrishna, Harish Gil-Higes, Emma Fernández-Ortiz, Antonio Macaya, Carlos Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design |
title | Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design |
title_full | Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design |
title_fullStr | Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design |
title_full_unstemmed | Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design |
title_short | Health Outcome Predictive Evaluation for COVID 19 international registry (HOPE COVID-19), rationale and design |
title_sort | health outcome predictive evaluation for covid 19 international registry (hope covid-19), rationale and design |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510540/ https://www.ncbi.nlm.nih.gov/pubmed/32989425 http://dx.doi.org/10.1016/j.conctc.2020.100654 |
work_keys_str_mv | AT nunezgilivanj healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT estradavicente healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT fernandezperezcristina healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT feltesgisela healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT vediaoscar healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT vergarauzcateguicarlose healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT morenomenguiavictorh healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT cerratoenrico healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT dascenzofabrizio healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT raposeirasroubinsergio healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT martinsanchezfjavier healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT alfonsorodriguezemilio healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT huangjia healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT ramakrishnaharish healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT gilhigesemma healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT fernandezortizantonio healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign AT macayacarlos healthoutcomepredictiveevaluationforcovid19internationalregistryhopecovid19rationaleanddesign |